AB Science webcast of March 4, 2024
04/03/2024 – Presentation of the AB Science webcast held on March 4, 2024
Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
01/03/2024 – AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALS
26/02/2024 – AB Science today announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26/01/2024 – AB Science announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure, instead of addressing these issues through the Oral Explanation
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006
AB Science webcast – Masitinib in Sickle Cell Disease
30/11/2023 – Presentation of the Masitinib in Sickle Cell Disease webcast
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease
28/11/2023 – AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
27/11/2023 – AB Science announces today that a new clinical development program for masitinib in sickle cell disease is among the 19 winning projects to be funded under the sixth call for “Hospital-University Research in Health” (Recherche Hospitalo-Universitaire en santé) projects, which part of the Future Investments Program
Revenues for the first half of 2023 and update on AB Science’s activities
29/09/2023 – AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
18/09/2023 – AB Science today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) timetable for examination of the masitinib marketing authorization application in amyotrophic lateral sclerosis (ALS)